| 1.855 -0.125 (-6.31%) | 07-15 15:25 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.7  |
1-year : | 3.16 |
| Resists | First : | 2.31 |
Second : | 2.7 |
| Pivot price | 1.39 |
|||
| Supports | First : | 1.2 |
Second : | 0.5 |
| MAs | MA(5) : | 1.78 |
MA(20) : | 1.28 |
| MA(100) : | 0.62 |
MA(250) : | 0.59 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 73.5 |
D(3) : | 73.5 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 2.31 | Low : | 0.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IPA ] has closed below upper band by 18.4%. Bollinger Bands are 457.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 26 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.03 - 2.04 | 2.04 - 2.05 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.96 - 1.98 | 1.98 - 2 |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Mon, 14 Jul 2025
ImmunoPrecise Secures Nasdaq Future: How Their Bio-AI Platform Helped Drive Share Price Recovery - Stock Titan
Mon, 07 Jul 2025
ImmunoPrecise Antibodies Appoints Jon Lieber to Board of Directors - citybiz
Sun, 06 Jul 2025
ImmunoPrecise Antibodies’ LENSai Platform Achieves Breakthrough in Epitope Mapping Accuracy - Yahoo Finance
Tue, 24 Jun 2025
Even With A 72% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely - simplywall.st
Thu, 12 Jun 2025
ImmunoPrecise’s AI-Designed Peptides Surpass Semaglutide in Receptor Activation - TipRanks
Tue, 20 May 2025
AI Breakthrough: ImmunoPrecise CEO Reveals Next-Gen Biotherapeutics Strategy at Major Tech Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 8.5 (%) |
| Shares Short | 1,390 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | -1.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | -194.8 % |
| Operating Margin | -53.5 % |
| Return on Assets (ttm) | -14.9 % |
| Return on Equity (ttm) | -124.8 % |
| Qtrly Rev. Growth | -1.2 % |
| Gross Profit (p.s.) | 0.26 |
| Sales Per Share | 0.52 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.51 |
| PEG Ratio | 0 |
| Price to Book value | 3.37 |
| Price to Sales | 3.53 |
| Price to Cash Flow | -10.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|